research use only

Bedaquiline ATPase inhibitor

Name: Bedaquiline
Brand: Selleck Chemicals
SKU: S5623
Availability: InStock
Rating: 5 (5 reviews)

Cat.No.S5623

Bedaquiline (TMC-207, R207910), a diarylquinoline, binds to subunit c of mycobacterial ATP synthase and inhibits its activity. It is highly selective for the mycobacterial ATP synthase enzyme compared to the homologous eukaryotic enzyme (Selectivity Index >20 000).

Chemical Structure

Molecular Weight: 555.50

Jump to

Quality Control

Batch: Purity: 99.99%

99.99

Related Targets	CFTR CRM1 CD markers AChR Calcium Channel Sodium Channel Potassium Channel GABA Receptor TRP Channel GluR
Other ATPase Inhibitors	(-)-Blebbistatin Thapsigargin Brefeldin A (BFA chemical) CB-5083 Golgicide A Sodium orthovanadate Bufalin Oleic Acid CDN1163 Ginsenoside Rb1

Solubility

In vitro
Batch:

DMSO : 33 mg/mL (59.4 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.670mg/ml (3.01mM)	Taking the 1 mL working solution as an example, add 50 μL of 33.3 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	555.50	Formula	C₃₂H₃₁BrN₂O₂	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	843663-66-1	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	TMC-207, R207910			Smiles	CN(C)CCC(C1=CC=CC2=CC=CC=C21)(C(C3=CC=CC=C3)C4=C(N=C5C=CC(=CC5=C4)Br)OC)O

Mechanism of Action

Targets/IC₅₀/Ki	mycobacterial ATP synthase
In vitro	Bedaquiline targets against Mycobacterial ATP synthase complex. This compound has anti-cancer activity, directed against Cancer Stem-like Cells (CSCs). Its treatment of MCF7 breast cancer cells inhibits mitochondrial oxygen-consumption, as well as glycolysis, but induces oxidative stress. It reduces mitochondrial membrane potential, with a significant rise in ROS levels. It specifically inhibits mitochondrial respiration in cancer cells, while enhancing mitochondrial function in normal cells. This chemical dramatically inhibits oxygen consumption and ATP production in the low micromolar range. In addition, its treatment also reduced aerobic glycolysis.
In vivo	Bedaquiline follows triphasic elimination and characterized by an outstandingly long terminal half-life, around 173 h in humans.
References	[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930122 [2] https://pubmed.ncbi.nlm.nih.gov/27344270/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05175794	Recruiting	Drug Resistant Tuberculosis\|MDR-TB\|XDR-TB\|Tuberculosis	Centre for the AIDS Programme of Research in South Africa\|KNCV Tuberculosis Foundation\|Amsterdam Institute for Global Health and Development\|Ospedale San Raffaele\|Foundation for Innovative New Diagnostics Switzerland\|National Institute for Medical Research Tanzania\|University of St Andrews\|Global Alliance for TB Drug Development\|Wits Health Consortium (Pty) Ltd\|Institute of Human Virology Nigeria\|Ethiopian Public Health Institute	May 26 2022	--
NCT04239326	Completed	Tuberculosis Multidrug-Resistant	Foundation for Innovative New Diagnostics Switzerland	April 16 2021	--

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):